America’s research engine stalls: NIH funding slowdown rattles labs, careers, and scientific ambition

Something is off-tempo in the world’s most influential biomedical funding system, and universities are beginning to feel it in real time.

At the halfway mark of the federal fiscal year, the National Institutes of Health (NIH) has committed only a fraction of the money it is expected to distribute. An analysis released by the Association of American Medical Colleges shows that just $5.8 billion, about 15 percent of an estimated $38 billion budget, had been obligated as of last week. At the same point in the previous cycle, that figure was closer to $9 billion as reported by the NIH’s RePORTER site.

In federal terms, an “obligation” is not a casual promise; it is a formal signal to universities and research institutions that funds are available to be spent. The gap, therefore, is not technical; it is tangible.

A delayed start that is proving hard to recover from

The slowdown did not emerge in isolation. It began with last year’s prolonged government shutdown, which effectively stalled NIH’s grant-making machinery for the first seven weeks of the fiscal year. By the time funding activity resumed in December, the agency was already behind schedule.

The numbers since then suggest a system struggling to catch up. NIH obligated $1.2 billion in December, followed by $2 billion across January and February. That pace, while steady, falls short of historical trends. According to the AAMC’s assessment of NIH RePORTER data, the first half of this fiscal year has seen markedly lower funding activity than any of the past five years.

The worry now is less about delay and more about compression. If the pattern holds, NIH may once again be forced into a late-year sprint to meet its September 30 deadline, an approach that has consequences far beyond accounting.

When speed replaces strategy

Last year offered a preview of what that kind of sprint looks like. Faced with time constraints, NIH pushed out more than half of its annual research funding in the final three months of the fiscal year.

To do so, it leaned heavily on multiyear grants, large, extended commitments that allowed the agency to allocate funds quickly. The trade-off was immediate: Fewer new grants were awarded.

That contraction is already visible this year. Since October, NIH has issued just 1,187 new grants, 63 percent fewer than the average at this stage over the past five years, according to the AAMC data. For a research ecosystem that thrives on fresh proposals and new ideas, that drop is not just a statistic; it is a narrowing of possibility.

Universities begin to pull back

The strain is now surfacing inside campuses. The Association of American Universities has flagged a similar slowdown, with senior policy officials warning that NIH is “considerably far behind,” as reported by The Inside Higher Ed.

That lag is shaping decisions in admissions offices and laboratories alike. Some universities have reduced the number of Ph.D. students they admit in life sciences. Others are offering admissions with caveats, uncertain whether funding will materialise. Hiring freezes have become common; layoffs, in some cases, unavoidable.

These are not routine adjustments. Research universities operate on long timelines, where faculty hiring, student admissions, and lab investments are tightly interwoven with expected grant flows. When funding becomes unpredictable, institutions do what they must to manage risk, and that usually means scaling back.

The quiet squeeze on early-career scientists

The sharpest impact, however, is being felt by those with the least margin for delay: early-career researchers. Data from NIH and cited by the AAMC paints a stark picture. Applications for R01-equivalent grants, often the gateway to an independent research career, rose last year. Awards, however, fell. In 2024, about a quarter of applicants secured funding; in 2025, that share dropped noticeably despite a larger applicant pool.

These are scientists in their most precarious phase, typically within a decade of completing their training, often building their first labs, and working against tight professional timelines. A missed grant cycle can set them back years or push them out of academia altogether.

Ironically, this comes at a moment when NIH leadership has spoken about the need to back younger scientists and riskier ideas.

A deeper question of trust

Beyond the numbers and the timelines lies a more fundamental issue: confidence. Biomedical research does not operate on short cycles. It depends on sustained, predictable investment, on the assumption that ideas worth pursuing will have the time and resources they need to mature. When that assumption weakens, the effects ripple outward.

Graduate admissions shrink. Labs hesitate to expand. Researchers become more cautious in the questions they choose to pursue.

The AAMC, in its report, put it plainly: predictable funding is essential not only for scientific progress but for ensuring that public investment delivers meaningful returns.

Waiting for momentum

There are early signs that the situation could improve. Recent approvals of funding apportionments have raised expectations that NIH may pick up the pace in the coming weeks. Whether that acceleration will be measured and strategic, or compressed and reactive, remains uncertain.

For now, the system is in a holding pattern. Universities are adjusting, researchers are waiting, and the world’s largest biomedical funder is under pressure to prove that a slow start will not define the year.

Because in science, delays are rarely just delays. They are often detours, ones that can reshape who gets to participate, which ideas move forward, and how quickly discovery itself unfolds.
Ready to navigate global policies? Secure your overseas future. Get expert guidance now!